Departments of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sci Rep. 2020 Oct 20;10(1):17769. doi: 10.1038/s41598-020-72475-9.
To evaluate whether radiomic features from contrast-enhanced computed tomography (CE-CT) can identify DNA mismatch repair deficient (MMR-D) and/or tumor mutational burden-high (TMB-H) endometrial cancers (ECs). Patients who underwent targeted massively parallel sequencing of primary ECs between 2014 and 2018 and preoperative CE-CT were included (n = 150). Molecular subtypes of EC were assigned using DNA polymerase epsilon (POLE) hotspot mutations and immunohistochemistry-based p53 and MMR protein expression. TMB was derived from sequencing, with > 15.5 mutations-per-megabase as a cut-point to define TMB-H tumors. After radiomic feature extraction and selection, radiomic features and clinical variables were processed with the recursive feature elimination random forest classifier. Classification models constructed using the training dataset (n = 105) were then validated on the holdout test dataset (n = 45). Integrated radiomic-clinical classification distinguished MMR-D from copy number (CN)-low-like and CN-high-like ECs with an area under the receiver operating characteristic curve (AUROC) of 0.78 (95% CI 0.58-0.91). The model further differentiated TMB-H from TMB-low (TMB-L) tumors with an AUROC of 0.87 (95% CI 0.73-0.95). Peritumoral-rim radiomic features were most relevant to both classifications (p ≤ 0.044). Radiomic analysis achieved moderate accuracy in identifying MMR-D and TMB-H ECs directly from CE-CT. Radiomics may provide an adjunct tool to molecular profiling, especially given its potential advantage in the setting of intratumor heterogeneity.
评估对比增强计算机断层扫描(CE-CT)的放射组学特征是否可以识别 DNA 错配修复缺陷(MMR-D)和/或肿瘤突变负担高(TMB-H)的子宫内膜癌(ECs)。纳入了 2014 年至 2018 年间接受原发性 ECs 靶向大规模平行测序和术前 CE-CT 的患者(n=150)。ECs 的分子亚型使用 DNA 聚合酶 epsilon(POLE)热点突变和基于免疫组化的 p53 和 MMR 蛋白表达来分配。TMB 来自测序,以 >15.5 个突变/兆碱基作为定义 TMB-H 肿瘤的切点。在提取和选择放射组学特征后,使用递归特征消除随机森林分类器处理放射组学特征和临床变量。使用训练数据集(n=105)构建的分类模型,然后在保留测试数据集(n=45)上进行验证。集成的放射组学-临床分类使用受试者工作特征曲线(AUROC)下的面积区分 MMR-D 与拷贝数(CN)低样和 CN 高样 ECs,为 0.78(95%CI 0.58-0.91)。该模型进一步区分了 TMB-H 与 TMB-L 肿瘤,AUROC 为 0.87(95%CI 0.73-0.95)。肿瘤周围边缘的放射组学特征与这两种分类都最相关(p≤0.044)。放射组学分析在直接从 CE-CT 识别 MMR-D 和 TMB-H ECs 方面具有中等准确性。放射组学可能为分子谱分析提供一种辅助工具,尤其是在肿瘤内异质性方面具有潜在优势。